Opicinumab
- Generic Name
- Opicinumab
- Drug Type
- Biotech
- CAS Number
- 1422268-07-2
- Unique Ingredient Identifier
- WX1WTN0Y15
- Background
Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 419
- Registration Number
- NCT01864148
- Locations
- 🇺🇸
OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States
🇨🇦Research Site, Montreal, Quebec, Canada
🇺🇸Stanford University Medical Center, Stanford, California, United States
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Phase 1
Completed
- Conditions
- Multiple SclerosisRelapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT01244139
- Locations
- 🇺🇸
Research Site, Centennial, Colorado, United States
BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 72
- Registration Number
- NCT01052506
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath